AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2021
Sep 2, 2021
31868_dirs_2021-09-02_591dba63-97cd-4bd4-8d47-d1acea60dcb7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2021-08-31
Reporting Person: ASELAGE STEVE (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-08-31 | Common Stock | A | 314 | $15.92 | Acquired | 32444 | Direct |
Footnotes
F1: Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $10,000.
More from BIOCRYST PHARMACEUTICALS INC
Regulatory Filings
2026
Jun 29
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 12
Call Transcript
2026
Jun 3
Call Transcript
2026
May 12
Interim / Quarterly Report
2026
May 6
Call Transcript
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23